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Abstract
Kainate receptors (KARs) are a subfamily of ionotropic glutamate receptors (iGluRs) mediating excitatory synaptic trans-
mission. Cell surface expressed KARs modulate the excitability of neuronal networks. The transfer of iGluRs from the 
endoplasmic reticulum (ER) to the cell surface requires occupation of the agonist binding sites. Here we used molecular 
modelling to produce a range of ligand binding domain (LBD) point mutants of GluK1–3 KAR subunits with and without 
altered agonist efficacy to further investigate the role of glutamate binding in surface trafficking and activation of homomeric 
and heteromeric KARs using endoglycosidase digestion, cell surface biotinylation and imaging of changes in intracellular 
 Ca2+ concentration  [Ca2+]i. Mutations of conserved amino acid residues in the LBD that disrupt agonist binding to GluK1–3 
(GluK1-T675V, GluK2-A487L, GluK2-T659V and GluK3-T661V) reduced both the total expression levels and cell surface 
delivery of all of these mutant subunits compared to the corresponding wild type in transiently transfected human embryonic 
kidney 293 (HEK293) cells. In contrast, the exchange of non-conserved residues in the LBD that convert antagonist selectivity 
of GluK1–3 (GluK1-T503A, GluK2-A487T, GluK3-T489A, GluK1-N705S/S706N, GluK2-S689N/N690S, GluK3-N691S) 
did not alter the biosynthesis and trafficking of subunit proteins. Co-assembly of mutant GluK2 with an impaired LBD and 
wild type GluK5 subunits enables the cell surface expression of both subunits. However,  [Ca2+]i imaging indicates that the 
occupancy of both GluK2 and GluK5 LBDs is required for the full activation of GluK2/GluK5 heteromeric KAR channels.
Keywords Kainate receptors · Glutamate · Ligand binding · Site-directed mutagenesis · Subunit assembly · Trafficking · 
Ca2+ imaging
Abbreviations
AMPA  (S)-2-Amino-3-hydroxy-5-methyl-4-isoxazole-
propionic acid
[Ca2+]i  Intracellular  Ca2+ concentration
ConA  Concanavalin A
ECL  Enzyme chemiluminescence
EndoF  Peptide-N-glycosidase F
EndoH  Endoglycosidase H
ER  Endoplasmic reticulum
GABA  γ-Aminobutyric acid
GFP  Green fluorescent protein
GluA1-4  AMPA receptor subunit 1–4
GluK1–5  According to the new IUPHAR nomenclature 
the KAR subunits that were formerly known 
as GluR5–7 (or GLUK5–7) are now named 
GluK1–3 and those previously called KA-1 
and KA-2 (or GLUK1 and GLUK2) are now 
named GluK4 and GluK5.
[3H]MG  [3H]-(2S,4R)-4-methylgutamate
iGluR  Ionotropic glutamate receptor
HEK  Human embryonic kidney
KA  Kainate, (2S,3S,4S)-3-carboxymethyl-4-iso-
propenyl-pyrrolidine-2-carboxylic acid
KAR  Kainate receptor
LBD  Ligand binding domain
NMDA  N-Methyl-d-aspartate
WT  Wild type
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Introduction
Kainate receptors (KARs) are members of the ionotropic 
glutamate receptor (iGluR) family [1, 2]. Presynaptically 
KARs modulate neurotransmitter (glutamate, GABA) 
release, postsynaptically they contribute to the slow com-
ponent of excitatory postsynaptic current (EPSC), thereby 
influencing neuronal excitability and network dynamics 
[1, 3]. In addition to ionotropic activities, KARs exert 
their effects through metabotropic signalling pathways 
[4]. There are five KAR subunits: GluK1–5 (previously 
GluR5–7, KA-1 and KA-2) with different functional roles. 
Each subunit contributes to the formation of the KAR 
channel pore and contains a unique ligand binding domain 
(LBD) [5] with distinctive pharmacological properties [6]. 
The majority of native KARs are tetramers, made up of 
heteromeric combinations of GluK1–5 subunits [7]. Gluta-
mate binding to the LBD triggers the opening of the KAR 
ion channel, which is permeable to  Na+ and  K+ [6]. Q/R 
editing in the channel pore forming domains of GluK1 
and GluK2 determines the  Ca2+ permeability of KARs 
[8]. KAR localisation at the cell surface is regulated by 
trafficking motifs for endoplasmic reticulum (ER) reten-
tion and ER export, alternative splicing, editing, associ-
ated proteins, post-translational modifications and actions 
of pharmacological and molecular chaperones [9, 10]. 
GluK1–3 traffic to the cell surface in both homo and het-
eromeric forms. However, GluK4 and GluK5 possess ER 
retention signals which are only alleviated in heteromeric 
assemblies with GluK1–3 [11–13]. Disruption of ligand 
binding to GluK2 leads to intracellular retention of subu-
nits [14]. However, subunits with impaired LBD are able 
to assemble with other wild type (WT) KAR subunits with 
functional LBD, which enables their trafficking to the cell 
surface [14–16]. It has been proposed, that ligand binding 
in the ER is required for ER exit [17]. While functional 
activation of KARs may not be required, it is likely that 
glutamate binding induced conformational changes are 
necessary during biosynthesis and trafficking [14–17]. For 
example, the link between desensitization and ER exit has 
been made with KAR mutants, where engineered disulfide 
bridges across the ligand binding domain interface blocked 
GluK2 desensitization and retained mutant receptors in 
the ER [18].
Various KAR subunits have been implicated in differ-
ent neurological and psychiatric disorders (e.g. temporal 
lobe epilepsy [19–21], autism [22, 23], mental retarda-
tion [24], migraine [25], schizophrenia [26], depression 
[27] and bipolar disorder [28]). The involvement of KARs 
in these pathological conditions and the possible under-
lying cellular and molecular mechanisms are discussed 
in recent reviews [3, 29–31]. Therefore, KAR subunit 
selective ligands could have therapeutic potential [6]. The 
availability of crystal structures of KARs [5, 6] and the 
identification of key amino acid residues that are respon-
sible for specific pharmacological properties of subunits 
[32] created new opportunities for the production of novel 
ligands [33–35]. However, the development of selective 
and potent compounds and their functional characterisa-
tion require functional expression of recombinant KAR 
subunits in cell lines for electrophysiological analysis or 
fluorescence-based screening assays using fluorescent 
 Ca2+ indicators [6, 36, 37]. Previous studies typically used 
homomeric GluK1, GluK2 or GluK3 KARs expressed in 
human embryonic kidney 293 (HEK293) cells to test the 
subunit selectivity and pharmacological properties of new 
ligands [6, 33]. Due to the ER retention of GluK4 and 
GluK5 homomers, it was not possible to test their specific 
pharmacological characteristics in cell-based functional 
assays. Furthermore, there are indications that the agonist 
and antagonist sensitivity of heteromeric receptors can dif-
fer from recombinant homomeric KARs [38]. Therefore, 
testing the pharmacological properties of various KAR 
subunit ligand binding sites in heteromeric assemblies 
would be advantageous. Due to the presence of different 
functional LBDs in a heteromeric KAR assembly, studying 
the pharmacological characteristics of a specific ligand 
biding site in isolation and testing the subunit selectivity 
of a drug is very challenging.
Because each KAR subunit possesses its own ligand bind-
ing site, we hypothesised that using site-directed mutagen-
esis to disable the ligand binding to one subunit in a het-
eromer would allow the pharmacological investigation of 
the intact LBD in another subunit. This approach would be 
particularly advantageous for the development of GluK4 and 
GluK5 selective ligands using cell-based assays, because 
these subunits do not form functional KARs on their own 
due to their ER retention [6, 11–13]. In this study we ana-
lysed changes in the biosynthesis, stability, cells surface 
expression and agonist-induced responses of homomeric and 
heteromeric KARs with various LBD mutations to examine 
the interplay between different ligand binding sites.
Materials and Methods
Analysis of the Ligand Binding Sites
The X-ray crystal structure of the rat GluK2 LBD in com-
plex with kainate (Protein Data Bank identification code 
1TT1 [39]) was used as a template for homology modelling 
of the GluK1 and GluK3 subunit ligand binding sites using 
SWISS-MODEL and the resultant models were examined 
using Accelrys DS Visualizer 3.1 (Accelrys, Inc. San Diego, 
CA) [32]. The residues in the GluK2 LBD that are important 
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for agonist binding were mapped onto the LBDs of GluK1 
and GluK3 using linear sequence alignment to determine 
homologous binding site residues within these subunits. 
Similar methodology was used starting from the X-ray 
crystal structure of the rat GluK1 LBD in complex with the 
GluK1 selective antagonist UBP310 to determine equivalent 
residues that would be involved in antagonist binding in the 
LBDs of GluK2 and GluK3 (see [32] for details). Residue 
numbering used excludes the signal peptide.
Mutagenesis
The desired mutations of the human GluK1–2a(Q), 
GluK2a(Q) and GluK3a subunit encoding cDNAs were gen-
erated using the QuickChange II XL site directed mutagen-
esis kit (Stratagene, La Jolla, CA) following the protocol rec-
ommended by the manufacturer. Mutations were confirmed 
by full-length sequencing (Geneservice, Oxford, UK).
Cell Culture and Transfection
HEK293 cells were grown in Dulbecco’s modified Eagles 
medium (DMEM, Sigma, Gillingham, UK) containing 10% 
(v/v) fetal bovine serum (Biosera, Uckfield, East Sussex, 
UK), 100 µg/ml penicillin, 100 µg/ml streptavidin and 2 mM 
l-glutamine (all from Invitrogen Ltd., Paisley, UK) at 37 °C 
in a humidified atmosphere of 5%  CO2. For passaging, cells 
were washed three times in PBS (150 mM NaCl, 2.6 mM 
KCl, 10 mM  Na2PO4, 1.9 mM  KH2PO4, pH 7.4), detached 
in trypsin and resuspended in DMEM for plating. Cells were 
transiently transfected using linear polyethylene as described 
previously [32] and harvested 24 h following transfection.
Preparation of Membrane Fractions
Membrane fractions prepared from transiently transfected 
HEK293 cells were harvested in 10 mM  NaHCO3 with com-
plete protease inhibitor cocktail (Roche Diagnostics GmbH, 
Mannheim, Germany). Cells were lysed using an ultrasonic 
cell disruptor (2 × 10 s bursts at 10 W on ice; Microson, 
Qsonica, LLC., Newtown, CT, USA). Cell homogenates 
were centrifuged (1095×g, 20 min, 4 °C) to remove cellu-
lar debris. From the supernatants, membranes were pelleted 
at 40,000×g for 20 min at 4 °C. For radioligand binding 
assay, membranes were washed three times using repeated 
resuspension in 50 mM Tris (pH adjusted to 7.2 using citric 
acid) and centrifugation (40,000×g, 20 min, 4 °C). Protein 
concentrations were measured using a protein assay kit (Bio-
Rad Laboratories, Hemel Hempstead, UK) before membrane 
fractions were snap frozen in liquid nitrogen and stored at 
− 80 °C.
Radioligand Binding Assay
For radioligand binding assays using filtration with a 
Brandel cell harvester (model M-30; Brandel, Gaithers-
burg, MD, USA) [32], membranes were diluted in bind-
ing buffer (50 mM Tris buffered with citric acid, pH 7.2). 
Membrane proteins (150 µg) were incubated for 45 min 
with varying concentrations of  [3H]kainate (37 MBq/ml; 
PerkinElmer Life and Analytical Sciences, Waltham, MA) 
or  [3H]-(2S,4R)-4-methylgutamate  ([3H]MG; 50.6 Ci/mmol; 
Tocris Cookson, Bristol, UK) on ice. Kainate (1 mM) or glu-
tamate (1 mM) was added to parallel samples to determine 
nonspecific binding. Following rapid washing with binding 
buffer (3 × 4 ml), the radioactivity of filters was measured 
using a liquid scintillation counter (LS6500, Beckman High 
Wycombe, UK).
Endoglycosidase Digestion
Membrane fractions prepared from transiently transfected 
HEK293 cells were solubilised in 1% Triton X-100 and 
0.1% SDS in phosphate buffered saline (PBS; 150 mM 
NaCl, 2.6 mM KCl, 10 mM  Na2PO4, 1.9 mM  KH2PO4, pH 
7.4). Samples were centrifuged (21,255×g, 15 min, 4 °C) to 
remove debris. Endoglycosidase H (EndoH, 5 mU/100 µl of 
sample) or endoglycasidase F (EndoF; 1 U/100 µl of sam-
ple; Roche Diagnostics GMBH, Mannheim, Germany) were 
added to equal aliquots of solubilised membrane samples 
and incubated overnight at 37 °C [40] before immunoblot 
analysis.
Cell Surface Biotinylation
Transfected HEK293 cells were washed three times with 
PBS and incubated for 30 min in EZ-link sulfo-NHS-S-
S-biotin (0.5 mg/ml; Pierce Biotechnology, Rockford, IL, 
USA) as described previously [11, 41]. Membrane fractions 
prepared from cell surface biotinylated cultures were solubi-
lised in lysis buffer (1% triton X100, 0.5% deoxycholic acid, 
0.1% SDS, 1 mM EDTA, 100 mM NaCl, 50 mM Tris–HCl, 
pH 7.4 with complete protease inhibitor cocktail; Roche 
Diagnostics GmbH, Mannheim, Germany). Cellular lysates 
were centrifuged (21,255×g, 15 min, 4 °C) and 1/10th of 
the supernatant containing the solubilised membranes was 
used for acetone precipitation of proteins. To separate bioti-
nylated cell surface and non-biotinylated intracellular pro-
teins, the remaining fraction of lysate was incubated with a 
1:1 mixture of streptavidin agarose beads (Sigma-Aldrich 
Company Ltd., Gillingham, Dorset, UK) for 3 h at 4 °C with 
mixing by rotation. Beads were washed in lysis buffer and 
50 mM Tris–HCl (pH 7.5) before biotinylated cell surface 
proteins were eluted by heating (100 °C for 2 min) in SDS-
polyacrylamide gel electrophoresis (SDS-PAGE) sample 
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buffer (2% (w/v) SDS, 50 mM Tris–HCl (pH 6.8), 10% 
(v/v) 2-mercaptoethanol, 10% (v/v) glycerol and 0.1% (w/v) 
bromophenol blue) [11]. The β-actin content of biotinylated 
fractions was analysed on immunoblots to confirm that no 
intracellular proteins were labelled with biotin.
Cycloheximide Treatment of Cells
Twenty-four hours after transfection, HEK293 cells were 
treated with the protein synthesis blocker cycloheximide (50 
µg/ml; Sigma-Aldrich Company Ltd., Gillingham, Dorset, 
UK) to investigate potential differences in the degradation of 
wild type (WT) and mutant KARs subunits. Sister cultures 
were harvested at 0, 4, 8, 12, 24 and 36 h after the addition 
of cycloheximide and KAR subunit proteins were analysed 
in cell membrane lysates using immunoblotting as described 
previously [40].
Immunoblot Analysis
Following solubilisation in SDS-PAGE sample buffer, equal 
aliquots of proteins (10–20 µg/lane) were separated on 8% 
(w/v) SDS-PAGE gels and electrophoretically transferred 
onto polyvinylidene difluoride membranes [11]. Blots were 
probed with 0.1–0.5 µg/ml previously validate immunoaf-
finity purified polyclonal rabbit antibodies to GluK1 [32], 
GluK2/3 [42], GluK5 [42, 43] (Millipore, Watford, UK) and 
mouse monoclonal anti-β-actin antibody (Abcam, Cam-
bridge, UK). Previously described protocol was used to 
establish the linear sensitivity range of immunoreactivities 
for quantification using enzyme chemiluminescence (ECL) 
[44]. For the quantitative comparison of total KAR subunit 
levels, immunoreactivities were normalised to the β-actin 
content of each sample.
Measurements of  [Ca2+]i
Changes in intracellular  Ca2+ concentration  [Ca2+]i were 
measured by following changes in  Ca2+-sensitive dye 
(fura-2-AM; Sigma) fluorescence. Green fluorescent pro-
tein (GFP) co-expression was used to enable the identifi-
cation of cells that express KAR subunits (~ 12%). Trans-
fected HEK293 cells, that had been maintained for 24 h, 
were washed three times in HEPES buffered saline (HBS; 
135 mM NaCl, 5 mM KCl, 10 mM HEPES, 1 mM  MgCl2, 
2 mM  CaCl2, 30 mM glucose, pH 7.4) at 37 °C and loaded 
with 5 µM fura-2-AM in HBS for 45 min at 37 °C. Cells 
were than washed again in HBS three times and incubated 
for 15 min in the dark at room temperature (about 20 °C). 
Imaging was carried out using a continuous flow of HBS 
(2 ml/min at 20 °C) with a wash time of 5 min followed by 
addition of carbachol (10 µM) and kainate (25 µM; Toc-
ris Bioscience, Bristol, UK) in the presence of the KAR 
desensitisation blocker concanavalin A (ConA; 0.3 mg/ml; 
Sigma [45]) for 5 min with a 10 min wash in between drugs. 
Cells were visualised through a x20 objective on a Nikon 
eclipse TE2000-S microscope and a Hamatsu ORCA-ER 
camera (Hamatsu Photonics, Welwyn Garden City, UK). 
For ratiometric measurements, the emission at 510 nm 
was measured at 5 s intervals during alternate excitation 
at 340 nm and 380 nm for 200 ms, by a Lamda DG-4 light 
source and wavelength switcher (Sutter Instrument, Novato, 
CA, USA). The ratio of intensity of the emission at 340 nm 
and 380 nm (340/380 ration) was calculated by the Voloc-
ity software (PerkinElmer, Coventry, UK) and used as a 
measure of  [Ca2+]i. Matlab (Mathworks, Cambridge, UK) 
was used to calculate whether individual cells responded to 
kainate or carbachol. A positive response was recorded when 
340/380 ratio was more than twice the standard deviation of 
the baseline measured immediately before drug application.
Statistics
Statistical analysis was performed using an unpaired Stu-
dent’s t test. The ‘n’ represents the number of independ-
ent experiments. For non-equal ‘n’ numbers, a two-sample 
equal variance t test was performed. A ‘p’ value of less than 
0.05 was considered significant (*) and less than 0.02 was 
considered highly significant (**). Results are presented as 
mean ± SEM.
Results
Identification of Residues in GluK1–3 Subunits 
that are Involved in Ligand Binding
To identify conserved residues within the ligand binding 
domains (LBDs) of GluK1–3 subunits that are critical to 
glutamate binding, high resolution crystal structures of 
the GluK1 and GluK2 S1S2 domains [39] were analysed 
(Fig.  1). These models predicted that conserved amino 
acid residues in the GluK2 S1 domain (GluK2-A487) and 
GluK1–3 S2 domains (GluK1-T675, GluK2-T659 and 
GluK3-T661) are important for agonist binding. Mutation 
of these residues would interfere with glutamate binding, by 
creating steric clashes (GluK2-A487L; Fig. 1a) or through 
the loss of a hydrogen bond (GluK1-T675V; Fig. 1b). Steric 
occlusion in the GluK2-A487L mutant is achieved by replac-
ing the methyl group of GluK2-A487 with a bulkier isobu-
tyl group via replacement with a leucine residue, which 
extends deeper into the binding cavity, thereby preventing 
agonist binding. The hydroxyl group of GluK1-T675 forms 
an important hydrogen bond with the distal carboxylate of 
agonists such as glutamate and kainate and its replacement 
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with a methyl group in the GluK1-T675V mutant would 
therefore be expected to drastically reduce agonist affinity.
The identification and characterisation of non-conserved 
amino acid residues in the GluK1–3 S1 domains (GluK1-
T503, GluK2-A487 and GluK3-T489) and S2 domains 
(GluK1-S706, GluK2-N690 and GluK3-N691) that deter-
mine antagonist subunit selectivity without blocking ago-
nist binding to the receptor (Fig. 2) has been described in 
our previous study [32]. While the swapping of these non-
conserved residues between GluK1–3 converts the antago-
nist selectivity of subunits, glutamate and kainate binding is 
retained [32]. Therefore, these mutants that convert subunit-
selective characteristics of GluK1–3 LBDs (Fig. 2; [32]) 
together with wild type (WT) KAR subunits were used as 
controls in this study.
Mutation‑Induced Changes in  [3H]kainate and  [3H]
MG Binding to GluK1–3
To establish if the mutations that were introduced based on 
the crystal structure analysis had the desired effects on the 
agonist binding properties of mutant GluK1–3 KAR subu-
nits (Fig. 2), radioligand binding assays were performed 
using  [3H]kainate and  [3H]MG (Fig. 3). Mutations of con-
served residues in the GluK1–3 LBDs (GluK1-T675V, 
GluK2-A487L, GluK2-T659V and GluK3-T661V) sig-
nificantly reduced both  [3H]kainate (Fig. 3a) and  [3H]MG 
(Fig. 3b) binding activities. In contrast, exchanging A/T non-
conserved amino acid residues in GluK1 (GluK1-T503A) 
and GluK2 (GluK2-A487T) (Fig. 2b) produced no change 
in ligand binding activity compared to the corresponding 
WT subunits (Fig. 3a). The  [3H]kainate binding activities of 
GluK1-N705S/S706N, GluK2-S689N/N690S and GluK3-
N691S were shifted from the parent subunit towards that of 
the subunit the mutation was designed to imitate (Fig. 3a; 
[32]). These experiments confirmed that mutation of GluK1-
T675, GluK2-A487, GluK2-T659 and GluK3-T661 disrupts 
agonist binding.
Changes in the Expression Levels of Ligand Binding 
Site Mutant GluK1–3 Subunits
Expression levels of WT and LBD mutant GluK1–3 subunit 
proteins (Fig. 2) were assessed 24 h after transient transfec-
tion of HEK293 cells using immunoblot analysis (Fig. 4a). 
Previously characterised GluK1 [32] and GluK2/3 [11, 
32, 40, 42] specific antibodies were used for the identifi-
cation of KAR subunits (Fig. 4a). While the expression 
levels of GluK1–3 subunits with functional LBDs (GluK1-
N705S/706N, GluK1-T503A, GluK2-S689N/N690S, 
Fig. 1  Identification of amino 
acid residues critical to agonist 
binding. Molecular modelling 
based on the crystal structures 
of the S1S2 ligand binding 
domains of GluK1 and GluK2 
in complex with glutamate (pur-
ple) [39] was used to generate 
mutant subunits with impaired 
ligand binding sites. a It was 
predicted that glutamate binding 
can be prevented through the 
introduction of steric clashes 
by changing an Ala residue 
in the S1 domain of GluK2 
(GluK2-A487) to a bulkier Leu 
(green molecule). b Modelling 
indicated that glutamate forms 
a hydrogen bond (green dotted 
line in red circle) with a Thr res-
idue (green) in the S2 domain 
of GluK1 (GluK1-T675), which 
can be disrupted by mutating 
this residue to Val. (Color figure 
online)
Loss of hydrogen bond
GluK1-T675 (WT)
GluK1-T675V mutantGluK2-A487L mutant
T675
S2S2
S2 S2
S1S1
S1 S1
Steric clashes induced
GluK2-A487 (WT)
GluK1
V675 
A487
L487 
GluK2 BA
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GluK2-A487T and GluK3-N691S) were similar to WT, 
there was a marked reduction in the level of subunits with 
impaired ligand binding (GluK1-T675V, GluK2-A487L, 
GluK3-T661V; Fig. 4b). Investigation of the degradation 
rates of different LBD mutant GluK1–3 subunits (Fig. 2) 
using cycloheximide treatment [40] indicate no significant 
differences at any of the investigated time points (4, 8, 12, 24 
and 36 h following the addition of cycloheximide) compared 
to WT (not shown). These experiments indicate that there is 
a significant reduction in the level of GluK1–3 subunits with 
impaired ligand binding sites and this does not appear to be 
caused by increased degradation.
Comparison of Intracellular Trafficking of GluK1–3 
Containing Homomeric Wild‑Type and Ligand 
Binding Site Mutant KARs
Previous studies reported that LBD mutations that impair 
glutamate binding or prevent conformational changes can 
prevent the export of KAR subunit proteins to the cell 
Fig. 2  Mutation of key amino 
acid residues in the S1S2 ligand 
binding domains of GluK1–3. 
a Schematic model of kainate 
receptor (KAR) subunit with the 
S1S2 ligand binding sites and 
M1-4 membrane domains. Glu 
glutamate, N amino-terminus, C 
carboxy-terminus, EC extracel-
lular, IC intracellular. Insert 
illustrates membrane domains 
in the KAR ion channel, which 
is formed by four subunits. b 
Mutations in the S1S2 ligand 
binding sites of GluK1–3 that 
disrupt glutamate (Glu) binding 
(red) or convert subunit selec-
tive characteristics of GluK1–3 
without blocking Glu bind-
ing (blue; [32]). (Color figure 
online)
N
C
M1
M2
M3 M4
Glu
PDZ
S1 S2
P
Na+, Ca2+
KAR subunit KAR channel
EC
IC
A
B
Mutations of conserved residues that are critical to Glu binding
GluK2 A487L
GluK1 T675V
GluK2 T659V
GluK3 T661V
Exchange of non-conserved residues that convert subunit selectivity
GluK1 T503A
GluK2 A487T
GluK3 T489A
GluK1 N705S/S706N
GluK2 S689N/N690S
GluK3 N691S
GluK1 697-RQQSALVKNSDEGIQRVLTTD-717
1 2 --------SN-----------
GluK2 681-RRQSVLVKSNEEGIQRVLTSD-701
2 1 -------NS------------
GluK3 682-SKPSALVKNNEEGIQRTLTAD-703
3 1 ---------S------------
GluK1 494-RADLAVAPLTITYVREKVIDF-514
1 2 ---------A-----------
GluK2 478-KADLAVAPLAITYVREKVIDF-498
2 1 ---------T-----------
GluK3 480-KADLAVAPLTITHVREKAIDF-500
3 2 ---------A-----------
GluK1 666-EYGAVRDGSTMTFFKKSKIST-686
---------V-----------
GluK2 650-EYGAVEDGATMTFFKKSKIST-670
---------V-----------
GluK3 652-EYGAVKDGATMTFFKKSKIST-672
---------V-----------
GluK2 478-KADLAVAPLAITYVREKVIDF-498
---------L-----------
S2
S1
S2
S1
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surface [17, 46]. Therefore, we compared the trafficking of 
WT and LBD mutant homomeric GluK1–3 KARs by analys-
ing their glycosylation status by EndoH and EndoF digestion 
(Fig. 5) and cell surface biotinylation (Fig. 6). Our previ-
ous studies established that EndoH resistance directly cor-
relates to cell surface expression of KARs and can be used 
to monitor the processing of glycosylated subunits during 
their trafficking through the secretory pathway in transfected 
HEK293 cells and neurons [32, 40]. Therefore, we compared 
the EndoH resistant (higher molecular weight) KAR subunit 
protein bands that indicates trafficking through the Golgi, to 
EndoH sensitive (deglycosylated lower molecular weight) 
bands that represent ER-retained subunits (Fig. 5). Due 
to the endoplasmic reticulum retention of WT GluK1 [9], 
LBD mutants of this subunit (GluK1-T503A, GluK1-T675V 
and GluK1-N705S/S706N) displayed equally high level of 
EndoH sensitivity and low level of surface expression with 
no detectable differences between WT and mutants (Fig. 5b). 
As expected, ~ 50% of GluK2-WT and ~ 30% of GluK3-WT 
were EndoH resistant (Fig. 5), which is consistent with pre-
vious studies [32, 40]. While the EndoH/EndoF sensitivity 
profiles of mutant GluK2 and GluK3 with functional LBD 
(GluK2-S689N/N690S, GluK2-A487T, GluK3-N691S; 
Fig. 5) were very similar to the corresponding WT, subunits 
with impaired ligand binding displayed a significantly higher 
level of EndoH sensitivity (GluK2-T659V, GluK2-A487L, 
GluK3-T661V; Fig. 5).
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Fig. 3  Modification of conserved amino acid residues within the 
GluK1–3 S1S2 domains disrupts agonist binding. HEK293 cells 
were transiently transfected with wild type (GluK1-WT, GluK2-WT, 
GluK3-WT) or LBD mutant (GluK1-T675V, GluK1-T503A, GluK1-
N705S/S706N, GluK2-A487L, GluK2-T659V, GluK2-A487T, 
GluK2-S689N/N690S, GluK3-T661V, GluK3-N691S) GluK1–3 
KAR subunit containing plasmids. After 48 h membranes were iso-
lated and thoroughly washed by centrifugation and resuspension, 
before the radioligand binding assay was carried out. The presence of 
KAR subunits in membrane samples was confirmed using immunob-
lotting (not shown). Membrane fractions (150 µg protein/assay) were 
incubated with 100  nM  [3H]kainate in the presence (non-specific 
binding) and the absence (total binding) of 1 mM kainate a or 10 nM 
 [3H]-(2S,4R)-4-methylgutamate  ([3H]MG) in the presence (non-spe-
cific binding) and the absence (total binding) of 1 mM glutamate (b). 
While the mutation of conserved residues (GluK1-T675V, GluK2-
A487L, GluK2-T659V, GluK3-T661V) resulted a marked reduction 
in  [3H]kainate (a) and  [3H]MG (b) binding, exchanging residues 
between GluK1 and GluK2 at the T/A site of the S1 domain (GluK1-
T503A, GluK2-A487T) produced no significant change in  [3H]kain-
ate binding. The exchange of N/S residues at the S2 domain increased 
 [3H]kainate binding to GluK1-N705S/S706N and reduced the binding 
activity of GluK2-S689N/N690S and GluK3-N691S. LBD mutant 
GluK1–3 were compared to the corresponding WT subunit. Data are 
mean ± SEM (n = 3 independent determinations using three parallel 
samples in each experiment); **p < 0.01, ***p < 0.005, Student’s t 
test
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Changes in the surface expression of WT and LBD mutant 
GluK2 and GluK3 homomeric KARs was confirmed by sur-
face biotinylation of transiently transfected HEK293 cells and 
subsequent separation of biotin-labelled proteins by strepta-
vidin [11, 41]. Total (T), biotin labelled surface (S) and unla-
belled intracellular (I) protein fractions were analysed using 
immunoblotting [32, 40] (Fig. 6a). Cell surface expression 
levels were determined relative to the total KAR subunit 
content of the relevant samples (Fig. 6b). No immunoreac-
tivity to β-actin was detected in the biotinylated fractions of 
the subunits indicating that only proteins present on the cell 
surface were labelled (Fig. 6a). In agreement with the EndoH 
sensitivity profiles, there were no significant differences 
between the surface expression of mutant GluK2 and GluK3 
with functional LBD (GluK2-S689N/N690S, GluK2-A487T, 
GluK3-N691S; Fig. 6b) compared to the corresponding WT 
(GluK2-WT, GluK3-WT; Fig. 6b). In contrast, the cell surface 
expression of subunits with impaired LBD was significantly 
lower (GluK2-T659V, GluK2-A487L, GluK3-T661V; Fig. 6b) 
compared to the corresponding WT.
These experiments indicate that disruption of ligand bind-
ing to GluK2 or GluK3 prevents the cell surface expression of 
homomeric KARs.
The Effect of GluK5 Co‑expression on the Cell 
Surface Trafficking of GluK2 LBD Mutants
Cell surface expression of heteromeric assemblies of GluK2 
with functional (GluK2-WT, GluK2-S689N/N690S, GluK2-
A487T) and impaired (GluK2-T659V, GluK2-A487L) 
LBDs in combination with GluK5-WT was assessed using 
biotinylation of surface proteins in transiently transfected 
HEK293 cells (Fig. 7). While GluK5 alone is completely 
retained in the ER [11], co-expression with WT or any of 
A
B
Fig. 4  Mutations that disrupt agonist binding cause reduction in 
KAR subunit protein levels. a Membrane fractions prepared from 
transiently transfected HEK293 cells 24  h after transfection, were 
analysed using immunoblotting with previously validated GluK1 
and GluK2/3 subunit selective antibodies. To reveal potential quan-
titative differences in total KAR subunit expression levels, samples 
were prepared from sister cultures transfected at the same time with 
the various WT and mutant subunit constructs and processed in par-
allel for immunoblotting. ECL exposure time was adjusted to the 
linear sensitivity range of immunoreactivities to allow quantitative 
comparisons between bands identified by the same antibody. b KAR 
subunit immunoreactivities were normalised to the β-actin content of 
the sample. Mutant GluK1–3 subunits with impaired LBDs (GluK1-
T675V, GluK2-T659V, GluK2-A487L; red) show a significant 
decrease in subunit protein levels compare to the corresponding WT 
(GluK1-WT, GluK2-WT, GluK3-WT; white) or other LBD mutants 
that retained agonist binding activity (GluK1-N705S/S706N, GluK1-
T503A, GluK2-S689N/N690S, GluK2-A487T, GluK3-N691S; blue). 
Data are mean ± SEM (n = 3–4), *p < 0.05, Student’s t test. (Color 
figure online)
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the LBD mutant GluK2 enabled the surface expression of 
GluK2/GluK5 heteromers.
Co-expression with GluK5-WT also increased the cell 
surface expression of all GluK2 variants (GluK2-WT/
GluK5-WT: ~ 28%/~ 27%; GluK2-T659V/GluK5-WT: 
~ 28%/~ 26%; GluK2-A487L/GluK5-WT: ~ 14%/~ 14%; 
GluK2-S689N/N690S/GluK5-WT: ~ 12%/~ 10%; GluK2-
A487T/GluK5-WT: ~ 18%/~ 20%) compare to homomeric 
subunits (Fig. 6). This GluK5-WT co-expression-related 
increase in cell surface GluK2 was particularly prominent 
for mutant subunits with impaired LBD (~ sevenfold for 
GluK2-T659V and ~ fivefold for GluK2-A487L; Figs. 6, 7). 
This indicates that co-expression relieves the ER retention 
of both GluK5-WT and GluK2 with mutations that block 
ligand binding (GluK2-T690V, GluK2-A487L) and enables 
their cell surface trafficking as heteromers.
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Fig. 5  Homomeric KARs with impaired LBDs are retained in intra-
cellular compartments. a Solubilised membrane fractions obtained 
from transiently transfected HEK293 cells expressing WT and 
mutant GluK2 and GluK3 subunits for 24  h were deglycosylated 
with EndoH or EndoF as indicated and analysed using immunoblot-
ting with a rabbit GluK2/3 specific antibody. While EndoH resistant 
GluK2 and GluK3 were identified around 105  kDa (R, black arrow 
heads), the EndoH sensitive subunits showed a molecular weight 
reduction to ~ 95 kDa (S, white arrow heads). EndoF enzyme treat-
ment of GluK2 and GluK3 produced a single band with molecular 
weight of ~ 93 kDa. Due to the identified differences in total expres-
sion levels of various KAR subunit mutants (Fig. 4), immunodetec-
tion of bands was optimised separately for the quantitative compari-
son of EndoH and EndoF sensitive/resistant bands for each construct. 
b Mutants with impaired LBDs (GluK2-T659V, GluK2-A487L and 
GluK3-T661V; red) show greater EndoH sensitivity than the cor-
responding WT subunits. In contrast, LBD conversion mutants of 
GluK2 and GluK3 that retain ligand binding (GluK2-S689N/N690S, 
GluK2-A487T, GluK3-N691S) show no significant change in EndoH 
sensitivity compared to WT. There were no detectable differences in 
the EndoH sensitivity of GluK1-WT, GluK1-T503A, GluK1-N705S/
S706N and GluK1-T675V. Data are mean ± SEM (n = 3), *p < 0.05, 
***p < 0.005, Student’s t test. (Color figure online)
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Functional Characterisation of Homomeric 
and Heteromeric KARs
Kainate (25 µM) induced changes in intracellular  Ca2+ 
concentration  ([Ca2+]i) were analysed using a fluores-
cence-based assay in transiently transfected HEK293 
cells expressing GluK2-WT, GluK2-T659V, GluK2-
A487L, GluK2-S689N/N690S or GluK2-A487T either 
as homomeric receptors or in combination with GluK5-
WT (Fig.  8). GFP was used as a marker to identify 
transfected HEK293 cells (~ 12%) that express KAR 
subunits. The muscarinic acetylcholine receptor agonist 
carbachol (10 µM) was used to confirm the responsive-
ness of transfected cells. Following the investigation of 
agonist-induced  [Ca2+]i responses, cells were routinely 
harvested for immunoblot analysis to verify the expres-
sion levels of KAR subunits. Activation (kainate, 25 µM) 
of mutant GluK2 subunits with functional ligand binding 
sites (GluK2-S689N/N690S, GluK2-A87T) produced very 
similar  [Ca2+]i responses to GluK2-WT, which was not 
altered significantly by the co-expression of GluK5-WT 
subunit (Fig. 8). This indicates that exchanging non-con-
served residues that convert pharmacological properties 
of the GluK2 LBD but retain ligand binding [32] (Fig. 3), 
does not alter receptor function. In contrast, GluK2 
mutations that impair the LBD (GluK2-T659V, GluK2-
A487L; Fig. 3) abolished kainate (25 µM) evoked  [Ca2+]i 
responses compared to GluK2-WT (Fig. 8). Co-expression 
of GluK5-WT with GluK2-T659V or GluK2-A487L does 
not rescue receptor function and only very few transfected 
A
B
Fig. 6  Thr/Val and Ala/Leu mutations reduce cell surface expres-
sion of GluK2 and GluK3 subunit proteins. a Transiently transfected 
HEK293 cells expressing wild type (GluK2-WT, GluK3-WT) or 
mutant subunits with impaired ligand binding sites (GluK2-T659V, 
GluK2-A487L, GluK3-T661V; red) or conversion mutants with func-
tional ligand binding sites (GluK2-S689N/N690S, GluK2-A487T, 
GluK3-N691S; blue) were surface biotinylated 24 h after transfection. 
Following the solubilisation of membranes (total; T), biotin-labelled 
(cell surface exposed; S) proteins were separated from non-bioti-
nylated (intracellular; I) proteins using streptavidin coated beads. The 
different subunit populations were analysed using immunoblotting 
with a GluK2/3 specific antibody. The β-actin content of the samples 
was analysed to confirm that biotinylation only labelled cell surface 
exposed proteins in transfected HEK293 cells. Due to differences 
in total expression levels of various KAR subunit mutants (Fig.  4), 
immunodetection of bands were optimised for the quantitative com-
parison of biotinylated and non-biotinylated (intracellular) bands for 
each construct. b Bar diagrams compare the biotinylated (surface) 
fractions of subunits expressed as % of total. Mutants with impaired 
LBDs (GluK2-T659V, GluK2-A487L and GluK3-T661V; red bars) 
show reduced cell surface expression (biotinylation) than the cor-
responding WT subunits (white bars). In contrast, LBD conversion 
mutants of GluK2 and GluK3 that retain ligand binding (GluK2-
S689N/N690S, GluK2-A487T, GluK3-N691S; blue bars) show no 
significant change in cell-surface biotinylation compare to WT. Data 
are mean ± SEM (n = 3), *p < 0.05, Student’s t test. (Color figure 
online)
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cells responded to kainate (Fig. 8), despite the presence 
of functional LBDs in GluK5 and improved cell surface 
expression of GluK2/GluK5 heteromers (Fig. 7). This 
suggests that agonist binding to GluK5 alone is not suf-
ficient for the opening of the ion channel and functional 
GluK2 LBDs are required for the activation of GluK2/
S689N
N690S
T659V A487L A487T
S689N
N690S
T659V A487L A487T
* * * * 
G
lu
K2
G
lu
K2
G
lu
K2
G
lu
K2
0 
10
20
30
40
WT
GluK5
GluK2
WT WT WT WT WT
%
 o
f t
ot
al
WT WT
WT
G
lu
K2
G
lu
K5
G
lu
K2
G
lu
K5
G
lu
K2
G
lu
K5
G
lu
K5
G
lu
K5
G
lu
K5
G
lu
K5
G
lu
K2
G
lu
K5
G
lu
K2
G
lu
K5
G
lu
K2
G
lu
K5
G
lu
K5
G
lu
K5
G
lu
K2
G
lu
K5
Surface GluK2 and GluK5
A 
B 
40
100
M
ol
. W
t x
 1
03
 
T S T S T S T S T S T S 
GluK2
β-actin
GluK5
100
Fig. 7  GluK5 co-expression restores the cell surface trafficking of 
GluK2 with Thr/Val or Ala/Leu mutations. a Wild type (WT) and 
mutant GluK2 subunits (GluK2-T659V, GluK2-A487L, GluK2-
S689N/N690S, GluK2-A487T) were co-expressed with the GluK5 
WT subunit in transiently transfected HEK293 cells. Following sur-
face biotinylation, labelled proteins (S) were isolated using strepta-
vidin coated beads and analysed using immunoblotting using anti-
GluK2/3 and anti-GluK5 antibodies. T is 10% of total protein. The 
β-actin immunostaining confirmed that biotinylation only labelled 
cell surface exposed proteins. b Comparison of surface (biotinylated) 
GluK2 and GluK5 subunits (% of total) indicates no significant dif-
ferences between the various LBD mutant and WT subunits (Data 
are mean ± SEM, n = 3, *p < 0.05, Student’s t test). As expected, the 
intracellularly retained GluK5-WT [11] was not detectable on the cell 
surface when it was expressed without GluK2
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GluK5 heteromers. Due to the fast desensitisation rate of 
GluK3 that cannot be blocked by the addition of ConA 
[47], we did not include GluK3 in  [Ca2+]i imaging studies.
Discussion
We found that mutations of conserved residues in the 
LBDs (GluK2-A487, GluK1-T675, GluK2-T659, GluK3-
T661) hindered both kainate and MG binding to all low 
affinity subunits of KARs. In contrast, exchanging non-
conserved T/A amino acid residues between GluK1 and 
GluK2 subunits (GluK1-T503A, GluK2-A487T, GluK3-
T489A) did not alter kainate binding. While reciprocal 
mutations of the non-conserved N/S residues in GluK1–3 
(GluK1-N705S/S706N, GluK2-S689N/N690S, GluK3-
N691S) enabled agonist binding, the kainate binding 
activities of mutant subunits shifted from the parent 
subunit towards that of the subunit the mutation was 
designed to imitate. In line with previous studies, muta-
tions that impair ligand binding to GluK2 and GluK3 also 
disrupted the trafficking of homomeric KARs and lead 
to the intracellular retention of these subunit proteins 
[17, 46] (Fig. 9). In contrast, exchanging non-conserved 
residues in the GluK2 and GluK3 LBDs has no significant 
effect on their glycosylation and cell surface expression 
profiles. Co-assembly with the WT high affinity GluK5 
subunit can override ER retention of mutant GluK2 with 
impaired LBD and promotes the cell surface expression of 
both subunits. However,  [Ca2+]i imaging indicates that the 
occupancy of both GluK2 and GluK5 LBDs is required for 
the full activation of heteromeric KAR channels (Fig. 9).
Previous studies revealed that ligand binding and asso-
ciated conformational changes are necessary for the bio-
genesis of KARs and their trafficking from the ER through 
the Golgi network to the cell surface in both homo- and 
heteromeric assemblies [14–16, 46, 48]. Our study of con-
served and non-conserved residues in the LBDs of GluK1–3 
with impaired and maintained ligand binding activities con-
firmed and extended these studies to other KAR subunits 
and amino acid residues. While the occupancy of the LBD 
enhances the cell surface expression of KARs, the opening 
of the ion channel pore appears to be not necessary [14, 
46]. However, restricting the ligand-induced conformational 
changes reduces the cell surface expression of KARs [15, 
18, 46]. The intracellular retention is not due to gross pro-
tein misfolding, because LBD mutant KAR subunits are 
capable of assembly [14, 15] and do not show increased 
Fig. 8  Thr/Val and Ala/Leu mutations of GluK2 abolish kainate-
induced responses of both homomeric GluK2 and heteromeric 
GluK2/GluK5 receptors. Wild type (WT) or mutant (GluK2-T659V, 
GluK2-A487L, GluK2-S689N/N690S, GluK2-A487T) GluK2 was 
expressed as homomer or heteromer with WT GluK5 in HEK293 
cells as indicated. Following incubation with fura-2-AM, 25 µM kain-
ate-induced increase in  [Ca2+]i was measured in GFP positive trans-
fected cells. GluK2 mutants with impaired LBD (GluK2-T659V and 
GluK2-A487L; red bars) have significantly fewer cells that respond 
to kainate with an increase in  [Ca2+]i compare to GluK2-WT or 
subunit conversion mutants (GluK2-S689N/N690S, GluK2-A487T; 
blue bars). Co-expression of GluK5-WT has not altered the kainate-
evoked responses of LBD mutant GluK2 subunits. Data are mean ± 
SEM (n = 3), *p < 0.05, ***p < 0.005 mutants compared to WT, Stu-
dent’s t test. (Color figure online)
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degradation rate [15]. Our results are consistent with these 
findings. When expressed individually, GluK2 subunits with 
impaired LBDs (GluK2-A487L, GluK2-T659V) and GluK5-
WT are all retained in the ER with very limited or no cell 
surface trafficking and no detectable change in degradation 
rates. However, when GluK2-A487L or GluK2-T659V was 
co-expressed with GluK5-WT, the ER retention domains of 
GluK5 [11, 12, 49] was shielded in the GluK2/GluK5 het-
eromer and enabled the surface expression of both subunits. 
This also suggests that glutamate binding to GluK5 alone 
is sufficient for the cell surface expression of the GluK2/
GluK5 complex. Indeed, the disruption of glutamate bind-
ing to GluK5 leads to a reduction in the plasma membrane 
expression and intracellular retention of GluK2/GluK5 
heteromers [15, 16]. Collectively these findings suggest a 
dominant role for the GluK5 LBD in the glutamate mediated 
cell surface trafficking of the GluK2/GluK5 complex. The 
GluK5 subunit may act as a possible modulator of GluK2 
trafficking or folding, ensuring that the protein reaches the 
correct conformation to be trafficked.
GluK2 and GluK5 are both widely expressed in the 
CNS [50] and they preferentially assemble [42] with 2:2 
stoichiometry [7] as pairs of heterodimers [51, 52] to form 
functional KARs. Unlike GluK2, GluK5 does not form 
functional homomeric channels even when the ER reten-
tion/retrieval motif is removed [15]. Because functional 
expression of GluK5 requires co-assembly with other 
KARs subunits, it is difficult to investigate the pharma-
cological properties of GluK5 in isolation. Newly syn-
thesised KAR antagonists are routinely tested on subunits 
expressed in HEK293 cells for their ability and selectivity 
to reduce l-glutamate induced calcium-influx by using a 
FlexStation [6, 33]. Based on previous studies we antici-
pated that the co-expression of GluK5-WT with impaired 
LBD containing GluK2 would provide a cell-based assay 
for the screening of GluK5 selective ligands. While the 
presence of the functional LBD in GluK5 and the masking 
of ER retention motifs in GluK5 by GluK2 LBD mutants 
enable the cell surface trafficking of GluK5-WT/GluK2-
T659V and GluK5-WT/GluK2-A487L heteromers, expo-
sure to kainate does not produce changes in  [Ca2+]i. This 
suggests that occupancy of GluK5 LBDs in the hetero-
meric assembly is sufficient for forward trafficking of the 
subunit assembly, but agonist binding to GluK2 is required 
for the opening of the KAR channel pore. Furthermore, 
previous pharmacological studies of GluK1/GluK5 het-
eromeric complexes demonstrated that GluK1 can gate 
current without concomitant activation of their partner 
GluK5 subunits and occupancy of binding sites on indi-
vidual KAR subunits activates distinct channel conduct-
ance and kinetic properties [53]. It is also possible to acti-
vate GluK2/GluK5 heteromers through agonist binding to 
the GluK2 subunit while GluK5 is inhibited by domoate 
[36, 54]. Even though the individual subunits can be acti-
vated separately, the GluK2 subunit may still need to be 
bound to a ligand and inducing a prolonged current before 
the GluK5 can react to bound agonist. Another possible 
explanation for the lack of activation seen in heteromeric 
assemblies is that when there is no ligand bound to the 
GluK2 subunit only the GluK5 subunit is able to react. It 
is not known if ConA effectively blocks the desensitisa-
tion of GluK5, which could mean that the GluK5 subunit 
is desensitising too quickly to produce a detectable change 
in  [Ca2+]i. However, electrophysiological studies suggest 
that activation of GluK5 subunits by agonist activates the 
KARs without inducing desensitisation [36, 55]. Another 
possibility is that the LBD dimer interface in the GluK5-
WT/GluK2-T659V and GluK5-WT/GluK2-A487L hetero-
dimers is not stable when the GluK5 LBD is closed, and 
the GluK2 LBD is open, which may promote entry into the 
Fig. 9  A schematic illustration of the assembly and trafficking of 
homomeric and heteromeric KARs with functional and impaired 
ligand binding sites. While GluK2 subunit proteins with functional 
LBD are readily expressed on the cell surface (PM plasma mem-
brane)  alone or in combination with GluK5, GluK2 with impaired 
ligand binding sites are retained in intracellular compartments (ER 
endoplasmic reticulum). The cell surface expression of GluK5 
depends on co-assembly with GluK2. Co-expression with GluK5 
restores the surface expression of GluK2 subunits with impaired LBD 
(red), but these receptors are non-functional despite the presence of 
active ligand binding sites in GluK5. This suggests that agonist bind-
ing to GluK5 is not sufficient to open the ion channel and activation 
of GluK2 is required for the activation of GluK2/GluK5 heteromeric 
KARs. (Color figure online)
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desensitised state and/or enhance the rate of deactivation. 
Stability of the dimer interface and of the hinge region, 
which serves as the pivot point for LBD closure, has been 
shown to be necessary to block desensitisation and slow 
deactivation, respectively, of AMPARs [56, 57]. While it 
is not possible to perform functional assays, it may be pos-
sible to use the GluK5-WT/GluK2-T659V and GluK5-WT/
GluK2-A487L heteromers in competition binding assays 
to screen compounds on GluK5.
The biosynthesis, assembly and cell surface trafficking 
of KARs are key determinants of neuronal network excit-
ability in the CNS [1, 3]. This study further highlights the 
pharmacological chaperone role of glutamate in KAR traf-
ficking and the differential functions of various subunits. 
Defining the distinct roles of various subunits is essential 
for the development of selective ligands for the targeted 
modulation of KARs in the CNS. Intriguingly, epilepsy-
associated mutations in the GluN2A NMDAR subunit that 
caused reduction in agonist potency also showed signifi-
cantly decreased expression levels and trafficking to the 
cell surface [58]. Functional and pharmacological analy-
ses of mutant KAR and other iGluR subunits [47, 58–60] 
would provide interesting insight into the molecular mech-
anism of associated neurological and psychiatric disorders.
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